SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 9.4% Stake in Cytokinetics Inc.
Beneficial Ownership Report (Schedule 13G Amendment)
FMR LLC and its affiliates, along with Abigail P. Johnson, have reported a beneficial ownership of 9.4% of Cytokinetics Inc.'s common stock as of December 31, 2024.
Summary
- FMR LLC, a Delaware-based parent holding company, and Abigail P. Johnson, a U.S. citizen and key figure within FMR LLC, have jointly filed an Amendment No. 5 to Schedule 13G.
- The filing reports their beneficial ownership of 11,146,953.56 shares of common stock in Cytokinetics Inc.
- This aggregate amount represents 9.4% of the total outstanding common stock of Cytokinetics Inc.
- FMR LLC holds sole voting power over 10,870,987.85 shares and sole dispositive power over 11,146,953.56 shares.
- Abigail P. Johnson holds sole dispositive power over 11,146,953.56 shares, with no shared voting or dispositive power reported by either party.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Cytokinetics Inc.
Sentiment
Score: 7
Explanation: The disclosure of a significant stake by a major institutional investor like FMR LLC is generally viewed positively by the market, signaling confidence in the company.
Positives
- The disclosure of a significant 9.4% stake by a major institutional investor like FMR LLC can be viewed as a positive signal, indicating confidence in Cytokinetics Inc.'s long-term prospects.
- The statement that the shares were acquired and are held in the ordinary course of business suggests a long-term investment perspective rather than an activist intent.
Risks
- None mentioned in this beneficial ownership filing, as Schedule 13G primarily focuses on ownership disclosure rather than operational or financial risks of the issuer.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Cytokinetics Inc.'s future performance or strategic direction, as it is solely a beneficial ownership disclosure.
Industry Context
FMR LLC, as the parent company of Fidelity Investments, is one of the largest asset managers globally. Their significant stake in Cytokinetics Inc., a biotechnology company, indicates continued institutional interest in the life sciences sector, particularly in companies with potential for therapeutic advancements.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Clarification | The filing clarifies that members of the Johnson family, including Abigail P. Johnson, are the predominant owners of Series B voting common shares of FMR LLC (49% voting power) and, through a shareholders' voting agreement, may be deemed to form a controlling group with respect to FMR LLC. | N/A | This clarifies the internal control structure of the reporting entity (FMR LLC) but does not indicate any changes to Cytokinetics Inc.'s corporate governance. |
Stakeholder Impact
- Shareholders: Increased institutional ownership by a reputable firm like FMR LLC may enhance investor confidence and potentially stabilize or positively influence the stock price.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership as of this date). |
| 2025-02-11 | Date of filing of Schedule 13G Amendment No. 5. |
Keywords
Cytokinetics Inc., FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.